Pfizer’s smoking-cessation drug Chantix nudged closer to blockbuster status last year, bringing in $997 million in sales—up 18% from 2016. But some portion of that may have come from price hikes, judging from a new report released by GoodRx, an aggregator of pricing and discount information on prescription drugs.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,